Product Characterization from Gene to Therapeutic Product

Medicines from Animal Cell Culture

Volumn , Issue , 2007, Pages 433-442

  Baker, Kym ^a   Flatman, Stephen ^a   Birch, John ^a  

^a LONZA AG   (Switzerland)

Author keywords

Characterization data for recombinant therapeutics; Physicochemical characterization; Product characterization; Product stability testing; Stability analysis

Indexed keywords

EID: 84889432496     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470723791.ch22     Document Type: Chapter

References (11)

1. Catlin DH, Breidbach A, Elliott S, Glaspy J (2002) Clin. Chem.; 48: 2057-2079.
2. Egrie JC, Browne JK (2001) Br. J. Cancer; 84(Supp1): 3-10.
3. Food and Drug Administration (FDA) Final Rule on 21 CFR Parts 314 and 601: 'Postmarketing Studies for Approved Human Drug and Licensed Biological Products'; Department of Health and Human Services, FDA; 27 February 2001) Federal Register, Vol. 65, No 210, October 30, 2000/Rules and Regulations.
4. ICH Steering Committee (10 March 1999) ICH Harmonized Tripartite Guideline Q6B: Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products.
5. James DC, Baker KN (1999) In Encyclopedia of Bioprocess Technology. Eds Flickinger MC, Drew SW John Wiley & Sons, Inc. New York; 1336-1349.
6. Lucore CL, Fry ET, Nachowiak DA, Sobel BE (1998) Circulation; 77: 906-914.
7. Rao P, Williams A, Baldwin-Ferro A et al. (1991) BioPharm.; Nov/Dec: 38-43.
8. Walsh G (2003) Nature Biotechnol.; 21: 865-870.
9. Wright JF (1997) Eur. J. Par. Sci.; 2(4): 103-108.
10. Yan SC, Razzano P, Chao YB et al. (1990) Bio/Technol.; 8: 655-661.
11. Yan SC, Chao YB, van Halbeek H (1993) Glycobiology; 3: 597-608.